BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Drug Development

  NuCana on the Rocks After Key Asset Fails in Biliary Tract Cancer

  Shares of NuCana have plunged more than 57% in premarket trading after the company announced its Phase III biliary tract cancer study. See more facts here.

  March 3, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  Business

  Cancer Immunotherapy Market Expected to Exceed $34B by 2030

  A new market research report by InsightAce Analytic projects the immuno-oncology or cancer immunotherapy market will hit $34.69 billion by 2030.

  March 3, 2022

   · 

  4 min read

   · 

  Mark Terry
• 

  Drug Development

  Roche Plans Ambitious Phase III Alzheimer’s Study

  The clinical trial, called SKYLINE, is starting without results from other key ongoing studies on the drug.

  March 3, 2022

   · 

  2 min read

   · 

  Hannah Chudleigh
• 

  Drug Development

  Research Roundup: New Insights into Alzheimer’s, ALS and FTD

  APOE4 is associated with an increased risk of Alzheimer’s disease. A European consortium coordinated by the University of Geneva believes they have identified at least one mechanism of action.

  March 3, 2022

   · 

  5 min read

   · 

  Mark Terry
• 

  Civica Plans to Provide Insulin at No More than $30 per Vial

  At this time, Civica plans a recommended price to the consumer of no more than $30 per vial and no more than $55 for a box of five pen cartridges. It believes it can have these versions of insulin available by 2024.

  March 3, 2022

   · 

  3 min read

   · 

  Mark Terry
• 

  Lone Star Bio

  CRISPR-Cas9 Redesign Reduces Mismatches, Potentially Improving Safety

  Researchers at the University of Texas at Austin shared results showing that their redesign of Cas9 makes it 4,000 times less likely to target the wrong stretch of DNA while still maintaining its efficiency.

  March 3, 2022

   · 

  2 min read

   · 

  Hayley Shasteen
• 

  Business

  With New Funds, Foresite’s Bajaj Outlines Coming Life Sciences Transformation

  Foresite Labs CEO Vikram Bajaj believes that data science will fundamentally transform the life sciences and translate into the development of new therapeutics for various disease states.

  March 3, 2022

   · 

  4 min read

   · 

  Alex Keown
• 

  Business

  Layoffs at Biogen Begin as Aduhelm Rollout Continues to Disappoint

  After months of speculation about looming layoffs, Biogen is handing out pink slips in order to save about $500 million.

  March 3, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  Business

  Sanofi, AstraZeneca Express Optimism Over Phase III Infant Respiratory Syncytial Virus Results

  In the Phase III MELODY trial, researchers found a 74.5% lower incidence of respiratory syncytial virus-caused pneumonia, and bronchiolitis. Here’s more about it.

  March 3, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Policy

  Life Sciences Industry Condemns Russian Invasion, Responds Accordingly

  On Wednesday, Massachusetts-based ConforMIS said it was suspending all distribution of its orthopedic medical devices to Russia and any Russian-based entities.

  March 3, 2022

   · 

  3 min read

   · 

  Alex Keown